Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2029 in Multiple Myeloma
NCT06700395Phase 1Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2029 in multiple myeloma (MM), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose at 18 months and 2 more. Started Nov 2024; status: recruiting.
02
Drugs
TQB2029
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06700395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06700395.